Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
The aim of this study was to compare the efficacy and safety of trastuzumab versus the combination of trastuzumab and lapatinib added to neoadjuvant chemotherapy for HER2 positive breast cancer. PubMed, MEDLINE, The Cochrane Library, Web of Science and nearly 5 years of the important international...
Main Authors: | Quan Liang, Qiang Fu, Wei Li, Jiacong You, Zhanchao Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Bangladesh Pharmacological Society
2016-10-01
|
Series: | Bangladesh Journal of Pharmacology |
Subjects: | |
Online Access: | https://www.banglajol.info/index.php/BJP/article/view/27384 |
Similar Items
-
Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
by: Ma W, et al.
Published: (2019-01-01) -
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
by: Tejal A. Patel, et al.
Published: (2019-09-01) -
The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
by: Chen ZL, et al.
Published: (2016-05-01) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)